Invention Grant
- Patent Title: Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
-
Application No.: US16069146Application Date: 2017-01-11
-
Publication No.: US10889643B2Publication Date: 2021-01-12
- Inventor: Natalia Arenas-Ramirez , Iwan Beuvink , Onur Boyman , Barbara Brannetti , Andreas Katopodis , Simone Popp , Catherine Regnier , Chao Zou
- Applicant: Novartis AG , Universität Zürich
- Applicant Address: CH Basel; CH Zürich
- Assignee: Novartis AG,Universität Zürich
- Current Assignee: Novartis AG,Universität Zürich
- Current Assignee Address: CH Basel; CH Zürich
- Agency: Inhouse Patent Counsel, LLC
- Agent Michele M. Wales
- International Application: PCT/IB2017/050127 WO 20170111
- International Announcement: WO2017/122130 WO 20170720
- Main IPC: C07K16/24
- IPC: C07K16/24 ; C12N5/10 ; C12N15/63 ; C07K14/55 ; A61K39/00 ; A61K38/00
Abstract:
The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
Public/Granted literature
Information query
